Research progress in the regulation of programmed cell death 1 receptor and its ligand pathway and the strategies against tumor drug resistance
10.3760/cma.j.cn114015-20190516-00422
- VernacularTitle:程序性细胞死亡1受体及其配体通路的调控与肿瘤耐药对策的研究进展
- Author:
Aqing XIE
1
;
Lin WANG
Author Information
1. 华中科技大学同济医学院附属武汉中心医院检验科 430075
- Publication Type:Journal Article
- Keywords:
Programmed cell death 1 receptor;
Antitumor drug, immunology;
Drug resistance, tumor
- From:
Adverse Drug Reactions Journal
2020;22(4):257-261
- CountryChina
- Language:Chinese
-
Abstract:
The overexpression of programmed cell death 1 receptor (PD-1) on the surface of T cells and programmed cell death 1 ligand 1 (PD-L1) secreted by tumor cells in tumor tissue inhibits the cellular immune response to a certain degree, so that the growth of tumor cells can escape the surveillance and clearance of the immune system. PD-1/PD-L1 inhibitors are specific protein antibodies designed for the expression of PD-1 or PD-L1, which can prevent the interaction between PD-1 and PD-L1 on tumor cells, thus partially restore T cell function and enhance tumor cell killing by T cells. However, because of the increasingly prominent drug resistance of PD-1/PD-L1 inhibitors in clinical applications, their efficacy cannot be sustained or even there were non-response to drugs in some patients. Recent studies have found that the expression of PD-1 and PD-L1 is regulated by many immune factors, and the transport and degradation processes of PD-L1 are also affected by many factors, such as glycosylation, phosphorylation, ubiquitination, and so on. The researches on the regulatory factors that may interfere in the PD-1/PD-L1 pathway will help to develop new treatment strategies to overcome drug resistance of PD-1/PD-L1 inhibitors in tumor, thereby improving the efficacy of tumor immunotherapy.
